Months after an FDA panel voted against Amylyx Pharmaceuticals’ amyotrophic lateral sclerosis drug, a second panel reversed the decision in a surprise vote before the agency approved the controversial ALS treatment Sept. 29.
Copyright © 2024 | WordPress Theme by MH Themes